Goldman Sachs analyst Andrea Tan raised the firm’s price target on Tarsus Pharmaceuticals to $30 from $19 and keeps a Neutral rating on the shares after its Q4 results. The company reported a strong Q4 beat with Xdemvy sales of $13.1M, above expected, driven by broader adoption by eye care providers, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TARS:
- Tarsus Pharmaceuticals reports Q4 EPS ($1.31), consensus ($1.36)
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Is TARS a Buy, Before Earnings?
- Tarsus Pharmaceuticals announces results from Carpo, phase 2a trial of TP-05
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
